Long-Term Weight Loss Data With Saxenda Announced

New clinical trial data presented at ObesityWeek 2015 showed that treatment with Saxenda (liraglutide; Novo Nordisk) in combination with a reduced-calorie diet and increased physical activity led to significant and sustained weight loss over 3 years vs. a reduced-calorie diet and  increased physical activity alone (placebo). 

The 3-year extension part of the Phase 3a SCALE™ (Satiety and Clinical Adiposity: Liraglutide Evidence in Non-Diabetic and Diabetic adults) Obesity and Pre-diabetes study included 2,254 adults with obesity or who were overweight with comorbidities and had prediabetes at baseline. 

RELATED: Liraglutide Linked to Greater Weight Loss Over 56 Weeks in T2DM

At Week 160, patients treated with Saxenda had an average body weight loss of 6.1% from baseline vs. 1.9% for placebo (P<0.0001). Weight loss ≥5% was seen in 49.6% of patients treated with Saxenda vs. 23.7% for placebo (P<0.0001). Data also showed 24.8% of patients lost >10% of their body weight with Saxenda vs. 9.9% with placebo (P<0.0001). 

The extension trial achieved the primary endpoint showing that continued treatment with Saxenda in combination with a reduced-calorie diet and increased physical activity delayed the onset of type 2 diabetes vs. placebo. 

Saxenda injection, a glucagon-like peptide-1 (GLP-1) receptor agonist, is available as prefilled multi-dose pens delivering doses of 0.6mg, 1.2mg, 1.8mg, 2.4mg, or 3mg (6mg/mL, 3mL) in 3- and 5-count cartons.

For more information call (800) 727-6500 or visit Saxenda.com.

Loading links....